Intensified lipid-lowering treatment with alirocumab in patients with coronary heart disease.

Daniel SteffensPeter BramlageJulia MüllerCornelia DornW Dieter PaarCeline ScheeffMario KasnerU Rauch-Kröhnert

Published in: Open heart (2021)

In a real-world setting in Germany, alirocumab was prescribed for patients with atherosclerotic cardiovascular disease who had high baseline LDL-C levels with or without statin intolerance. Efficacy and safety were consistent with findings observed in the ODYSSEY Phase III programme.

Keyphrases

phase iii
cardiovascular disease
low density lipoprotein
open label
clinical trial
phase ii
double blind
study protocol
coronary artery disease
type diabetes
placebo controlled
metabolic syndrome
cardiovascular risk factors
cardiovascular events
randomized controlled trial
smoking cessation